Back

Watch Compare

Curanex Pharmaceuticals Inc

Data quality: 83%

CURX

Nasdaq Manufacturing Chemicals

$0.47

▲ $0.03 (5.63%)

Mkt Cap: 13.28 M

Price

$0.47

Mkt Cap

13.28 M

Day Range

$0.43 — $0.48

52-Week Range

$0.26 — $9.18

Volume

82,720

Open $0.44

50D / 200D Avg

$0.39

21.50% above

50D / 200D Avg

$1.13

58.47% below

Quick Summary

Key Takeaways

Negative free cash flow of -10.48 M

Growth

Revenue Growth (5Y)

N/A

Revenue (1Y)N/A

Earnings (1Y)N/A

FCF Growth (3Y)N/A

Quality

Return on Equity

-57.89%

Below sector avg (-53.41%)

ROIC-44.64%

Net MarginN/A

Op. MarginN/A

Safety

Debt / Equity

N/A

Current Ratio77.53

Interest Coverage-496.55

Valuation

PE (TTM)

-3.14

Below sector avg (-1.48)

P/B Ratio0.93

EV/EBITDAN/A

Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)

Metric	Stock	Sector Median
P/E	-3.1	-1.5
P/B	0.9	1.6
ROE %	-57.9	-53.4
Net Margin %	—	-41.5
Rev Growth 5Y %	—	1.8
D/E	—	0.3

All Fundamental Metrics

Growth
Revenue Growth (1Y)	N/A	Revenue Growth (3Y)	N/A
Earnings Growth (1Y)	N/A	Earnings Growth (3Y)	N/A
Revenue Growth (5Y)	N/A	Earnings Growth (5Y)	N/A
Profitability
Revenue (TTM)	N/A	Net Income (TTM)	-4.23 M
ROE	-57.89%	ROA	-55.36%
Gross Margin	N/A	Operating Margin	N/A
Net Margin	N/A	Free Cash Flow (TTM)	-10.48 M
ROIC	-44.64%	FCF Growth (3Y)	N/A
Safety
Debt / Equity	N/A	Current Ratio	77.53
Interest Coverage	-496.55	Asset Turnover	N/A
Working Capital	14.23 M	Tangible Book Value	14.29 M
Dividends
Dividend Yield	N/A	Payout Ratio	N/A
Dividend Growth (3Y)	N/A	Dividend Growth (5Y)	N/A
Consecutive Div Years	N/A
Valuation
P/E Ratio	-3.14	Forward P/E	N/A
P/B Ratio	0.93	P/S Ratio	N/A
PEG Ratio	N/A	Forward PEG	N/A
EV/EBITDA	N/A	Fwd EV/EBITDA	N/A
Forward P/S	N/A	Fwd Earnings Yield	N/A
FCF Yield	-78.93%
Market Cap	13.28 M	Enterprise Value	7.48 M
Per Share
EPS (Diluted TTM)	-0.17	Revenue / Share	N/A
FCF / Share	-0.37	OCF / Share	-0.37
EPS CAGR (1Y)	N/A	EPS CAGR (5Y)	N/A
EPS CAGR (10Y)	N/A
Efficiency
CapEx / Revenue	N/A	FCF Conversion	248.15%
SBC-Adj. FCF	N/A	Growth Momentum	N/A

Income Statement

Annual, most recent first

Metric	FY2025
Revenue	—
Net Income	-4.23 M
EPS (Diluted)	-0.17
Gross Profit	—
Operating Income	-4.24 M
EBITDA	—
R&D Expenses	2.99 M
SG&A Expenses	—
D&A	—
Interest Expense	8,537.0
Income Tax	—

Balance Sheet

Annual, most recent first

Metric	FY2025
Total Assets	11.58 M
Total Liabilities	361,040.0
Shareholders' Equity	11.22 M
Total Debt	—
Cash & Equivalents	5.00 M
Current Assets	11.23 M
Current Liabilities	137,030.0